Compare Novartis AG (NVS) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Novartis AG is far larger — about 31.6× Global X NASDAQ 100 Covered Call ETF's market cap, and Novartis AG pays a 3.31% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| NVS | QYLD | |
|---|---|---|
Market Cap | $268.57B | $8.49B |
Volume | 1,532,573 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $18.68 |
52-Week Low | $121.80 | $16.70 |
Typical Hold Time | 82 Days | 51 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains a consistent monthly dividend payout of $0.18, providing an attractive yield for income-focused investors. Technical indicators present a mixed picture with an overall bullish signal from moving averages but bearish momentum from oscillators, while RSI levels suggest potential overbought conditions. Recent news highlights QYLD's role as a covered call ETF generating income through Nasdaq 100 options strategies.
The outlook for QYLD remains focused on income generation rather than capital appreciation, with the covered call strategy capping upside potential during market rallies. Key risks include declining option premiums, principal erosion over time, and tax treatment uncertainties. Investors should weigh the high monthly yield against the trade-off of limited participation in Nasdaq 100 growth, making it suitable for income needs but less ideal for long-term capital growth objectives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
